UPF
9.9.2021 17:53:11 CEST | Business Wire | Press release
A wide range of challenges stand in the way of building a stable and relatively peaceful global order for the 21st Century. Recent events related to the U.S. withdrawal from Afghanistan underscore this fact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005818/en/
Of critical importance to the geopolitical dynamics of our time is the ongoing crisis on the Korean Peninsula, which impacts East Asia and the rest of the world. While efforts toward peace have prevented another war in Northeast Asia, the potential for conflict still remains and would involve the U.S., China, Russia, and Japan. It is time for a new strategy to move toward reconciliation and cooperation on the Korean Peninsula.
Who: Think Tank 2022 Rally of Hope online is sponsored by the Universal Peace Federation (upf.org)
When: Sunday, September 12, 2021, 2:30 a.m. CET, Europe & Middle East (Live broadcast from South Korea) or Replay/Highlights: September 12, 2021, 6:00 PM CET
Where : Join the Live Event September 12th, at 02:30 AM (CET)
through this link: https://www.peacelink.live/online/
Join the Highlight Event September 12th, at 06:00 PM (CET)
through Zoom link: http://www.zoom.rallyofhope.eu/
or Live Facebook: http://www.facebook.rallyofhope.eu/
What: Inaugurated in 2020, the Rally of Hope is a series of live-streamed online productions using advanced augmented reality technology to connect millions of global viewers. Featuring prominent world leaders and captivating entertainment, the Rally of Hope is uplifting, actionable and faith-based.
Why: This new and unique program empowers the ordinary citizen who seeks meaningful change in their personal life, family, community, and even globally, by participating in a movement which transcends political, religious, racial, and ideological boundaries.
Previous Rallies of Hope have provided a platform for top experts to speak about the complex issues facing our planet, including: climate change, geopolitical hotspots, challenges of the coronavirus pandemic, honoring veterans of the Korean War on its 70th anniversary, the role of faith in peacebuilding, and much more.
The theme of the Think Tank 2022 Rally of Hope is “Steps Toward Peace in Asia: Focus on Reconciliation and Cooperation on the Korean Peninsula.” Although the Armistice Agreement brought an end to the hostilities, the Korean Peninsula continues to be a “storm center” for peace and security in the region. World leaders will speak about the risks and opportunities of resolving issues on the Korean Peninsula and steps toward peace in Asia.
Keynote Speakers : Kingdom of Cambodia Prime Minister Hun Sen , European Commission President
José Manuel Barroso (2004-2014), Republic of the Philippines President Gloria Macapagal Arroyo (2000-2010), Republic of India Prime Minister H.D. Deve Gowda (1996-1997), Trinidad and Tobago President Anthony Thomas Aquinas Carmona (2013-2018), and Republic of Serbia President Nataša Mićić (2002-2004). UPF Co-Founder Hak Ja Han Moon will offer a special message of hope in her Founder’s Address .
Find out more about the Rally of Hope & Think Tank 2022 here: https://www.rallyofhope.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005818/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom